Company Statements 2019

Biocon Biologics  /  News – Posts  /  Company Statements  /  Company Statements 2019

U.S. FDA Completes Pre-Approval Inspection of Two New Biocon Biologics Facilities in Bengaluru
  • Fri, 20-Sep-2019
  • Posted by: Biocon Biologics
No Comments

U.S. FDA Issues Complete Response Letter for New Drug Application for Insulin Glargine; Commercialization Plans Remain Unchanged
  • Sat, 31-Aug-2019
  • Posted by: Biocon Biologics
No Comments

U.S. FDA completes surveillance (routine) cGMP inspection of one of our Biologics Drug Product facilities in Bengaluru
  • Sat, 31-Aug-2019
  • Posted by: Biocon Biologics
No Comments

Pre-Approval U.S. FDA Inspection Conducted at Biocon’s Insulins Facilities in Malaysia
  • Mon, 08-Jul-2019
  • Posted by: Biocon Biologics
No Comments

Biocon Biologics Facilities in Bengaluru Receive EU GMP Certification
  • Fri, 14-Jun-2019
  • Posted by: Biocon Biologics
No Comments

Biocon Facility Completes Pre Approval U.S. FDA Inspection
  • Wed, 06-Mar-2019
  • Posted by: Biocon Biologics
No Comments
Report adverse event/ side effects and/or product complaints for Biocon Biologics products.

* Cookie Notice | Privacy Policy | Terms of Use © 2023, Biocon Biologics Limited (a Subsidiary of Biocon Limited). All Rights Reserved
Share